As big insulin makers pivot to GLP-1 blockbusters and exit the space, Biocon’s Kiran Mazumdar Shaw sees a rare opening to become the world’s dominant insulin company
Hot this week
Free News - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Get important news delivered directly to your inbox and stay connected!
